[1] |
Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.
Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study
[J]. Journal of International Oncology, 2024, 51(6): 326-331.
|
[2] |
Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.
Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy
[J]. Journal of International Oncology, 2024, 51(5): 257-266.
|
[3] |
Wang Kun, Zhou Zhongxin, Zang Qiwei.
Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection
[J]. Journal of International Oncology, 2024, 51(4): 198-203.
|
[4] |
Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.
Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma
[J]. Journal of International Oncology, 2024, 51(4): 210-216.
|
[5] |
Yao Yixin, Shen Yulin.
Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE
[J]. Journal of International Oncology, 2024, 51(4): 217-222.
|
[6] |
Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.
Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 137-142.
|
[7] |
Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.
Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes
[J]. Journal of International Oncology, 2024, 51(3): 143-150.
|
[8] |
Qian Xiaotao, Shi Ziyi, Hu Ge.
A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma
[J]. Journal of International Oncology, 2024, 51(3): 151-156.
|
[9] |
Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng.
Imaging diagnosis, pathological upgrade, and imaging technology progress of ductal carcinoma in situ of the breast
[J]. Journal of International Oncology, 2024, 51(3): 166-169.
|
[10] |
Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.
Progress of radiotherapy in oligometastatic non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 170-174.
|
[11] |
Liu Bohan, Huang Junxing.
Research progress of liquid biopsy technology in esophageal squamous cell carcinoma
[J]. Journal of International Oncology, 2024, 51(2): 105-108.
|
[12] |
Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng.
Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 83-88.
|
[13] |
Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.
Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 89-94.
|
[14] |
Ma Zhenghong, Jiang Chao.
Progress of KRASG12C mutations in non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 95-98.
|
[15] |
Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.
Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway
[J]. Journal of International Oncology, 2024, 51(1): 21-28.
|